Context: Carnitine and its metabolites are centrally involved in fatty acid metabolism. Although elevated circulating concentrations have been observed in obesity and insulin resistance, prospective studies examining whether these metabolites are associated with incident type 2 diabetes mellitus (T2D) are sparse.
T ype 2 diabetes mellitus (T2D) is a lifestyle-related disease characterized by insulin resistance causing impaired insulin-mediated glucose uptake in peripheral tissues (1) . Subjects with dysglycemia are at increased risk of microvascular and macrovascular disease even before the development of overt T2D (2) . Moreover, at least onethird of all cases of T2D may be undiagnosed (3) . Hence, there is need for improved identification of people at risk.
Recently, mitochondrial lipid overload and dysfunctional fatty acid oxidation (FAO) have been postulated to have important effects on the pathogenesis of insulin resistance and T2D (4) .
The quaternary ammonium compound carnitine is required for the shuttling of fatty acids into the mitochondrial matrix for FAO, a process during which esterified carnitines (acylcarnitines) are generated (5) . Carnitine is primarily obtained through diet but can be synthesized in vivo from its precursors trimethyllysine (TML) and g-butyrobetaine (Fig. 1) .
Cross-sectional studies have reported differences in serum acylcarnitine profiles between healthy individuals and those with obesity or T2D (6, 7) . Hence, circulating acylcarnitines have been proposed as potential biomarkers of dysregulated FAO associated with insulin resistance (8) . Recently, a casecontrol study identified palmitoylcarnitine as a novel marker of T2D in a targeted metabolomics approach (9) . Furthermore, we have observed that levels of the even-chained acetyl-, octanoyl-and palmitoylcarnitines predicted cardiovascular death and acute myocardial infarction in patients with stable angina pectoris (SAP) (10) . In the current study, we evaluated circulating carnitine, its precursors TML and g-butyrobetaine, as well as selected acylcarnitines of different chain lengths, in relation to incident T2D in a large prospective cohort of patients with suspected SAP.
Subjects and Methods

Study population
The source population has been described in detail elsewhere (10) . Briefly, it includes 4164 adults who underwent elective coronary angiography at two Norwegian university hospitals during 2000 through 2004. Of these, 2573 (61.8%) were subsequently included in the Western Norway B Vitamin Intervention Trial (ClinicalTrials.gov identifier no. NCT00354081) (11) . For the current study, we excluded 1603patients with either of the following: a self-reported diagnosis of diabetes mellitus at baseline (n = 496, of whom 37 reported type 1 diabetes mellitus), fasting plasma glucose level $ 7.0 mmol/L, nonfasting plasma glucose level $ 11.1 mmol/L, or glycated hemoglobin (HbA1c) $6.5%. In addition, 42 individuals who had missing HbA1c information were excluded. Hence, a total of 2519 eligible individuals were included in the final analyses.
Baseline information
The routines for collection of demographic, clinical, and biochemical baseline characteristics have been described in detail elsewhere (11) (12) (13) (14) . The participants were not routinely instructed to be fasting at the time of blood sampling but were requested to report the number of hours since their last meal; those Figure 1 . Carnitine biosynthesis and metabolism. The synthesis of carnitine via its precursors and its role in fatty acid metabolism are illustrated. g-BB, g-butyrobetaine; BBD, g-butyrobetaine dioxygenase; CACT, carnitine-acylcarnitine translocase; CAT, carnitine acetyl-transferase; CoA, coenzyme A; CPT1, carnitine palmitoyl-transferase 1; CPT2, carnitine palmitoyl-transferase 2; HTML, 3-hydroxy trimethyllysine; HTMLA, 3-hydroxy trimethyllysine aldolase; OCT2, organic cation/carnitine transporter; TMABA, 4-N-trimethylaminobutyraldehyde dehydrogenase; TMABADH, 4-Ntrimethylaminobutyraldehyde dehydrogenase; TMLD, trimethyllysine dioxygenase.
reporting .6 hours since their last meal were defined as fasting (15) . Significant obstructive coronary artery disease (CAD) was defined as having at least one epicardial coronary artery lesion stenosis of $50% of the artery diameter. Study-specific samples for the biobank were frozen at 280°C until analyzed during 2009 through 2011. Serum carnitine metabolite levels were determined by high-performance liquid chromatography-tandem mass spectrometry. The lower limits of detection and coefficients of varability have been reported previously (10) . The updated Homeostatic Model Assessments (HOMA2) of insulin resistance, b-cell function, and insulin sensitivity were calculated in a subgroup of fasting patients (n = 642) on the basis of serum C-peptide and plasma glucose levels (16) . Dietary information was collected from responses of 1336 patients at enrolment on a semiquantitative food-frequency questionnaire, as previously described (12) .
Study end point
Information on incident T2D was collected through 31 December 2009, as previously described (17) . In short, new cases of T2D were identified by having a first prescription of an oral glucose-lowering drug or insulin, as revealed through linkage to the Norwegian Prescription Database (www.norpd.no) from 2004 onward, or by identification according to hospital discharge diagnoses obtained from the Cardiovascular Disease in Norway (www.cvdnor.no) project (18, 19) . In addition, information on incident T2D was obtained from self-reports and verified by glucose measurements during in-trial follow-up of participants in the Western Norway B-Vitamin Intervention Trial (n = 1712; 67.9%) (11) .
Statistical analyses
Continuous and categorical variables are presented as median (25th, 75th percentile) and counts (percentage), respectively. Differences in baseline levels of carnitine pathway metabolites according to incident T2D were evaluated using the Mann-Whitney U test. Associations between continuous variables were calculated by Spearman ranked-correlation analyses adjusted for age, sex, and fasting status. Correlation coefficients are given as r. The values of nonnormally distributed serum acylcarnitines were log-transformed and standardized before entered into logistic regression models. Odds ratios (ORs) and 95% confidence intervals (CIs) are reported per standard deviation increment of log-transformed variables and obtained for three adjustment models: Model 1 included age, sex, and fasting status (yes vs no); model 2 included model 1, with further adjustment for body mass index (BMI); model 3 included model 2, with the addition of estimated glomerular filtration rate (eGFR), HbA1c, triglyceride and high-density lipoprotein (HDL) cholesterol levels, and study center. Subgroups were obtained from predefined categories or according to median values for continuous variables. We tested effect modifications according to median age, sex, fasting status (yes or no), median BMI, significant CAD at baseline (yes or no), median eGFR, median HbA1c value, median triglyceride and HDL cholesterol levels, and study center (dichotomous) by adding interaction product terms to the models.
For statistically significant predictors of incident T2D in the multivariable model 3, E-values were calculated for the point estimate and the lower confidence bound, according to the method of VanderWeele et al. (20) Because the event rate was relatively low in this cohort, the E-value was calculated on the basis of the OR (95% CI).
The relationships of TML, g-butyrobetaine, and palmitoylcarnitine as continuous variables to incident T2D were visualized by generalized additive regression curves in which the metabolites were modeled with a four degrees-of-freedom smoothing spline fit in multivariable logistic regression models. Model fit was compared using the Akaikes information criterion (21) . We explored model discrimination by calculating area under receiver operator characteristics curve (ROC-AUC). By determining continuous net reclassification improvement (NRI . 0), we evaluated whether the measurement of any of these metabolites could reassign a substantial number of participants into a more correct level of risk (22) .
All tests are two-tailed with a significance level set to P , 0.05, except for the correlation analyses, which were considered significant when P , 0.001. The statistical analyses were performed using the software packages SPSS Statistics, version 23.0 (IBM, Armonk, NY) for Apple OS X (Snow Leopard; Apple, Cupertino, CA), and Microsoft Windows 7 (Microsoft, Redmond, WA), and R versions 3.1.1 and 3.2.3 (23) for Apple OS X (Snow Leopard) and Microsoft Windows 7, respectively.
Results
Baseline characteristics of the prospective study population (n = 2519) are reported in Table 1 . In brief, the median (25th, 75th percentile) age was 62 (54, 69) years, 1841 of the participants (73.1%) were men, and 1888 (75.0%) had obstructive CAD. The median BMI was 26.0 (23.0, 28.0) kg/m 2 and HbA1c was 5.6% (5.0%, 6.0%). As shown in Supplemental Table 1 , there was a trend of g-butyrobetaine and free carnitine levels being lower, whereas acetyl-, propionyl-, (iso)valeryl-, and octanoylcarnitine levels were higher in those with alreadydiagnosed diabetes mellitus at baseline within the source population (N = 4164). When evaluated in patients without diabetes mellitus at inclusion (n = 2519), levels of TML, and propionyl-, (iso)valeryl-, octanoyl-, and palmitoylcarnitine were all significantly higher at baseline among those who subsequently developed T2D compared with those without T2D at the end of follow-up (P # 0.04; Table 2 ).
Other clinical characteristics stratified by diabetes status at baseline, as well as according to incident T2D during follow-up, have been published for this population previously (17) . In short, BMI, serum triglyceride levels, HOMA of insulin resistance, and prevalence of hypertension and significant CAD were higher at baseline among those who developed diabetes during follow-up.
In fasting participants, levels of acetyl-, octanoyl-, and palmitoylcarnitine were higher, whereas levels of TML, g-butyrobetaine, free carnitine, and propionyl-and (iso) valerylcarnitine were lower, compared with nonfasting participants (Supplemental Table 2 ).
Correlations between carnitine metabolites and relevant baseline parameters
In Spearman rank-correlation analyses adjusted for age, sex, and fasting status, TML showed positive associations with serum creatinine, insulin, and C-peptide levels, HOMA2 b-cell activity, and insulin resistance (r = 0.29 to 0.39); and a negative association with HOMA2 sensitivity (r = 20.37). Moreover, the precursor g-butyrobetaine was positively correlated with serum creatinine level (r = 0.39). The odd-chained acylcarnitines propionyl-and (iso)valerylcarnitine showed positive associations with serum insulin and C-peptide levels, HOMA2 b-cell activity, and insulin resistance (r = 0.29 to 0.37). Propionylcarnitine was also positively correlated with triglycerides (r = 0.28). All associations were statistically significant (P , 0.001).
Serum acylcarnitines and incident T2D
During a median follow-up of 7.7 (6.4, 8.7) years, a total of 173 new cases of T2D (6.9%) were registered. TML showed a significant positive association with incident T2D, which was only minimally attenuated by multivariable adjustment. In contrast, g-butyrobetaine was inversely associated with incident T2D, and the association became statistically significant by multivariable adjustment. ORs (95% CIs) for the multivariable adjusted model 3 were 1.22 (1.04 to 1.43) and 0.81 (0.66 to 0.98) per standard deviation increment for TML and g-butyrobetaine, respectively (Table 3) . No associations were found for free carnitine and acetylcarnitine with incident T2D. The remaining evaluated acylcarnitines predicted T2D in analyses adjusted for age, sex, and fasting status (model 1). However, these associations seemed to be confounded by BMI (model 2). After multivariable adjustment, only palmitoylcarnitine remained statistically significant associated with incident T2D (OR, 1.24; 95% CI, 1.04 to 1.49; Table 3 , model 3). Additional adjustments for baseline medications, smoking, and dietary energy intake did not affect the risk estimates appreciably; thus, they were not included in the final multivariate model. Estimates after adjustment for these potential confounders are shown in Supplemental Table 3 .
The estimates of TML, g-butyrobetaine, or palmitoylcarnitine were not affected by including any of them into the multivariate models of the others, indicating that associations are independent of each other. E-values for the observed ORs for TML, g-butyrobetaine, and palmitoylcarnitine were 1.74, 1.77, and 1.78, respectively. Sensitivity analysis applied to the confidence bound closest to 1 resulted in E-values of 1.16 to 1.24. The associations of TML, g-butyrobetaine, and palmitoylcarnitine with incident T2D are illustrated by generalized additive regression plots shown in Fig. 2 .
Because levels of all serum carnitine metabolites differed significantly according to fasting status, the risk associations of the metabolites with incident T2D were investigated in subgroups of participants who delivered nonfasting vs fasting blood samples with no evidence of effect modifications (Supplemental Fig. 1) . Moreover, the multivariable associations of TML, g-butyrobetaine, and palmitoylcarnitine with incident T2D were also consistent according to median age, sex, median BMI, significant CAD (yes or no), median eGFR, median HbA1c value, median triglyceride and HDL cholesterol levels, and study center (dichotomous). P for the interaction was $ 0.15. Model fit, discrimination, and reclassification analyses The addition of TML, g-butyrobetaine, or palmitoylcarnitine significantly improved goodness of fit for model 3 (Table 4) . g-Butyrobetaine and palmitoylcarnitine provided an NRI . 0 (95% CI) of 0.17 (0.01 to 0.33) and 0.18 (0.02 to 0.34), respectively. The addition of either metabolite to model 3 did not substantially affect the ROC-AUC values (0.714, 0.711, and 0.717 for TML, g-butyrobetaine, and palmitoylcarnitine, respectively, vs without any of these biomarkers, 0.709; P $ 0.18).
Discussion
Principal findings
In this study, we evaluated the association of selected carnitine metabolites, including precursors and five specific acylcarnitines, with incident T2D in patients with suspected SAP. During a median follow-up of almost 8 years, serum levels of the carnitine precursors TML and g-butyrobetaine and the esterified form, palmitoylcarnitine, predicted long-term risk of incident T2D independently of traditional risk factors. In general, ORs for the other carnitine metabolites were attenuated substantially after adjusting for BMI.
The carnitine pathway
Extensive experimental work has shown accumulation of carnitine pathway metabolites in obesity (24) . Carnitine is enzymatically synthesized in a stepwise manner from the amino acids lysine and methionine via several precursors, including TML and g-butyrobetaine ( Fig. 1) (5) . Carnitine exists as a wide variety of esterified species in the tissues and circulation; these are important mediators for FAO. Acylcarnitines are shuttled across the mitochondrial membranes by carnitine palmitoyltransferase and carnitine-acylcarnitine translocase ( Fig. 1) (25) . Subsequently, acylcarnitines are transesterified by carnitine palmitoyltransferase-2 into acyl-coenzyme As, which are further subject to b-oxidation. In the current study, five acylcarnitine species were evaluated that represented various chain lengths and forms. Even-chained short-, medium-, and long-chained species were represented by acetyl-, octanoyl-, and palmitoylcarnitine, respectively. Oddchained species were represented by propionyl-and (iso)valerylcarnitine, which typically originate from the catabolism of branched-chain amino acids (26) .
Previous studies
Free, active L-carnitine has been used extensively as a dietary supplement; its proposed beneficial effects include preventing atherosclerosis development (27) . T2D has been linked with carnitine deficiency, and several studies report reduced serum levels of carnitine among patients with diabetes (28) . In this aspect, carnitine has been used therapeutically in subjects with metabolic syndrome and cardiovascular disease, but with inconsistent results (27) . The current study did not reveal any difference in carnitine levels between those who subsequently developed T2D
and those who did not. However, among participants who already had diabetes mellitus at baseline in the source population, carnitine levels were significantly lower, suggesting that carnitine depletion may be a consequence of the disease rather than precede its development.
Although L-carnitine has been extensively studied in relation to metabolic disease, data on carnitine precursors are sparse. However, one study demonstrated elevated serum levels of both TML and g-butyrobetaine were associated with increased risk of cardiovascular death among patients with carotid atherosclerosis (29) . Moreover, TML has been linked to progression of coronary atherosclerosis in the same cohort (30) studied in the current report. Based on the strong association of T2D with cardiovascular disease, one may assume that a relatively large proportion of patients with CAD may be at risk of developing T2D (31) . In this study, we have demonstrated opposite associations of TML and g-butyrobetaine with risk of incident T2D.
In the current study, only a selection of acylcarnitines representing various chain lengths was measured. Hence, Figure 2 . Generalized additive regression plot of the association of serum TML, g-butyrobetaine, and palmitoylcarnitine with incident T2D in patients with SAP without diabetes mellitus. The solid lines in each graph denote the OR, and the gray areas indicate the 95% CI. The vertical white lines mark the 25th, 50th, and 75th percentiles on the superimposed density plot of the logarithmic TML, g-butyrobetaine, and palmitoylcarnitine concentrations along the x-axis. All panels show the multivariable adjusted model, which includes adjustments for age, sex, fasting status, BMI, eGFR, HbA1c, triglycerides and HDL cholesterol levels, and study center. The figure is cropped at the 2.5th and 97.5th percentile concentration levels. it is unclear whether the demonstrated risk association for palmitoylcarnitine is unique to this particular metabolite or reflects an overall association representing long-chained acylcarnitines in general. Elevated levels of long-chained acylcarnitines, including palmitoylcarnitine, have been demonstrated in obese patients and those with T2D, compared with lean individuals (6) . Moreover, altered levels of circulating acylcarnitines have been observed under prediabetic (32) and diabetic conditions (4) . Elevated palmitoylcarnitine levels have been associated with increased risk of incident T2D in a Chinese, nested case-control study (9) and with adverse events in a study investigating chronic heart failure (33). Interestingly, an in vitro study investigated the effect of fatty acid intermediates like palmitoylcarnitine on mitochondrial function in isolated rat myocytes; the authors concluded excessive amounts of palmitoylcarnitine may be detrimental for mitochondrial function by increased production of reactive oxygen species and by affecting the mitochondrial membrane potential (34) . We demonstrated an association of the even-chained acylcarnitines acetyl-, octanoyl-, and palmitoylcarnitine with risk of cardiovascular death or acute myocardial infarction in the source population of the current study (10) . We now also demonstrate that circulating palmitoylcarnitine independently predicts incident T2D. Notably, no significant effect modification according to CAD at baseline was seen. The three branched-chained amino acids valine, leucine, and isoleucine, which give rise to the odd-chained acylcarnitines, also predict incident T2D (4, 35), but we found no such association for propionyl-, or (iso) valerylcarnitine.
In the current study, overall risk estimates were substantially attenuated after adjusting for BMI, whereas only minimal changes to the estimates were observed after full adjustment for other potential confounders. This observation is in line with experimental studies showing accumulation of carnitine pathway metabolites in obesity (24) . Hence, TML and palmitoylcarnitine are the most promising biomarkers, also predicting T2D independently of BMI. Notably, however, the current study was performed using data from a defined cohort of elderly white patients, among whom the majority had obstructive CAD but an overall moderate BMI. This may partly explain why there were no significant associations of the odd-chained acylcarnitines with incident T2D. Thus, it is challenging to necessarily generalize these findings to other populations.
Possible mechanisms
TML is a product of the proteolytic degradation of endogenous triple-methylated lysine residues in proteins (36) , and its availability is considered to be rate limiting for carnitine biosynthesis (5). It is not clear why the plasma levels of TML and g-butyrobetaine related oppositely to T2D risk. However, it may be tempting to speculate that this may reflect a reduced conversion of TML into g-butyrobetaine among those at increased risk, which may indicate impaired carnitine biosynthesis (37) . Interestingly, g-butyrobetaine was positively associated with risk of cardiovascular death in a patient cohort having moderate or severe carotid atherosclerosis (29) . Notably, circulating g-butyrobetaine does not exclusively depend on the carnitine synthesis pathway but may be elevated by a gut microbiota-dependent mechanism. Hence, the apparent contradictory results may possibly reflect different underlying mechanisms. Carnitine deficiency occurs when there is a net loss of carnitine through urinary secretion and includes primary deficiency due to impaired function of the carnitine transporter OCT2, which is important in the kidneys for retaining carnitine within the body (38) , and secondary deficiency, characterized by elevated urinary secretion of acylcarnitines (39) . Although we did not observe any signs of carnitine deficiency in the current investigation, carnitine deficiency may be relevant as a long-term effect, based on the lower level of carnitine in those who had already developed diabetes mellitus at baseline in the source population. Thus, TML may be a risk predictor at the preclinical stage of disease, during a time when serum carnitine levels still are within a normal range. Subsequently, reduced serum carnitine levels may represent a long-term consequence of diabetes development.
Circulating acylcarnitines may be derived from several tissues, including liver, heart, and muscle. We measured carnitine metabolites in serum and interpretation regarding tissue-specific effects must be done with caution (40) . However, findings in insulin-resistant rats suggest serum acylcarnitines reflect the content in skeletal muscle, where a lipid substrate overload probably leads to excessive FAO (41) . Such diet-induced mitochondrial stress may eventually lead to an incomplete FAO and accumulation of fatty acid intermediates including not only acylcarnitines like palmitoylcarnitine but also diacylglycerols, long-chain fatty acyl-coenzyme As, and ceramides (42) . This further activates serine kinases, which subsequently activate proinflammatory cytokines like tumor necrosis factor-a and interleukin 6, as well as the nuclear factor-kB pathway. These signals have been linked with development of insulin resistance by interfering with insulin signaling (43) .
Identification of high-risk individuals and discovery of novel biomarkers for incident T2D is paramount for implementing preventive measures. To the best of our knowledge, this is the first study to present that circulating carnitine precursors are prospectively linked with incident T2D, a finding that suggests the carnitine synthesis pathway is a potential target in prevention or treatment of T2D. Our work also suggests that metabolites along the carnitine pathway may provide a metabolic signature of prognostic value when evaluating T2D risk. However, the clinical relevance of our findings needs further evaluation in future studies.
Strengths and limitations
This prospective study is based on a well-defined cohort of patients with suspected SAP with long-term follow-up. The study end points were gathered from the electronic patient administrative systems of two public hospitals and from the Norwegian Prescription Registry, which contains data on all outpatient prescriptions (i.e., dispensed medications) in Norway. We were not able to account for patients who were diagnosed with T2D but only received lifestyle interventions; hence, there is likely some underclassification of mild disease.
As in every prospective study, the possibility of residual confounding cannot be excluded despite careful adjustments for important available covariates. However, such confounding needs to be associated with the exposure metabolite and the outcome, to an extent, as described by the calculated E-values for the respective metabolites. We are not aware of any potential confounder of this strength that is not already included in the model. Even though the increments in ROC-AUC were not significant, the NRI was statistically significant for g-butyrobetaine and palmitoylcarnitine. In our opinion, this motivates further evaluation of a potential clinical application.
Notably, the current study was performed in a defined cohort of elderly patients, most of whom had obstructive CAD, but who had an overall moderate BMI. Hence, although we did not observe effect modifications according to age, BMI, or prevalent CAD, our findings need to be replicated in different populations.
Among individuals with suspected SAP, circulating concentrations of the carnitine precursors TML and gbutyrobetaine, and the long-chain ester palmitoylcarnitine predict long-term risk of T2D independently of traditional risk factors, possibly reflecting impaired carnitine synthesis and/or mitochondrial FAO in individuals susceptible to T2D development.
